

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	Not Yet Assigned 10/501054
				Filing Date	July 9, 2004
				First Named Inventor	Hamed Aissaoui
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	A0345.0003

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/MS/	BA	WO-01/45711-A1	06-28-2001	SMITHKLINE BEECHAM CORPORATION		
/MS/	BB	WO-01/45700-A1	06-28-2001	SMITHKLINE BEECHAM CORPORATION		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

/D Margaret Seaman/

06/21/2007



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	10/501,054-Conf. #1663	
			Filing Date	September 15, 2004	
			First Named Inventor	Hamed Aissaoui	
			Art Unit	1625	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	A0345.0003

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/MS/	BA	EP 0 428 434	05-22-1991	Sanofi S.A.		
	BB	WO 99/21835	05-06-1999	Fujisawa Pharmaceutical Co., Ltd.		
	BC	WO 01/09088	02-08-2001	Kirin Beer Kabushiki Kaisha		
	BD	WO 01/45694	06-28-2001	Smithkline Beecham Corporation		
	BE	WO 01/66143	09-13-2001	Takeda Chemical Industries, Ltd.		
	BF	WO 02/02530	01-10-2002	Takeda Chemical Industries, Ltd.		
	BG	WO 02/47687	06-20-2002	Smithkline Beecham Corporation		
	BH	WO 02/058702	08-01-2002	Smithkline Beecham Corporation		
	BI	WO 02/078641	10-10-2002	Smithkline Beecham Corporation		
	BJ	WO 02/078707	10-10-2002	Smithkline Beecham Corporation		
	BK	WO 02/079155	10-10-2002	Smithkline Beecham Corporation		
/MS/	BL	WO 02/079188	10-10-2002	Smithkline Beecham Corporation		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
/MS/	CA	Ames, R.S., et al., <i>Nature</i> (1999), 401, pp. 282-286			
	CB	Barlin G.B., et al., <i>Aust. J. Chem.</i> (1984), 37, pp 1065-1073			
	CC	Bern H.A., et al., <i>Recent Prog. Horm. Res.</i> (1985), 41, pp. 533-552			
	CD	Breu V., et al., <i>FEBS Lett.</i> (1993), 334, pp. 210-214			
	CE	Douglas S.A., et al., <i>Br. J. Pharmacol.</i> (2000), 131, pp. 1262-1274			
/MS/	CF	Douglas S.A., et al., <i>J. Cardiovasc. Pharmacol.</i> (2000), 36, Suppl. 1, pp. S163-166			
Examiner Signature	/D Margaret Seaman/			Date Considered	06/21/2007

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/501,054-Conf. #1663		
		Filing Date	September 15, 2004		
		First Named Inventor	Hamed Aissaoui		
		Art Unit	1625		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	A0345.0003

/MS/	CG	Garlton J., et al., <i>Psychopharmacology</i> (Berlin) (2001), 155, pp. 426-33	
	CH	Irving H., et al., <i>J. Chem. Soc.</i> (1959), p. 288	
	CI	Kaneko C., et al., <i>Chem. Pharm. Bull.</i> (1980), 28, pp. 1157-1171	
	CJ	Laguzza B.C., et al., <i>Tetrahedron Lett.</i> (1981), 22, pp. 1483-1486	
	CK	Liu Q., et al., <i>Biochem. Biophys. Res. Commun.</i> (1999), 266, pp. 174-178	
	CL	Mori M., et al., <i>Biochem. Biophys. Res. Commun.</i> (1999), 265, pp. 123-129	
	CM	Radinov R., et al., <i>Synthesis</i> (1986), pp. 886-891	
	CN	Russell F.D. et al., <i>Br. J. Pharmacol.</i> (2001), 132, pp. 5-9	
	CO	Silvestre R.A., et al., <i>Horm. Metab. Res.</i> (2001), 33, pp. 379-381	
	CP	Takahashi K., et al., <i>Peptides</i> (2001), 22, pp. 1175-1179	
	CQ	Totsune K., et al., <i>Lancet</i> (2001), 358, pp. 810-811	
	CR	Tsandes A., et al., <i>J. Am. Coll. Cardiol.</i> (2001), 37, p. 164A	
/MS/	S	Zou Y., et al., <i>FEBS Lett.</i> (2001), 508, pp. 57-60	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/D Margaret Seaman/	Date Considered	06/21/2007
-----------------------	---------------------	--------------------	------------